Yohei Kitamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yohei Kitamura has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Arnaldo Franco
Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
2 shared publications - Khalid Shah
Center for Stem Cell and Translational Immunotherapy, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
2 shared publications Masashi Nakatsukasa
Department of Neurosurgery, Saiseikai Utsunomiya Hospital, Utsunomiya, Tochigi, Japan
2 shared publications- Nobuhiko Kanaya
Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
2 shared publications Abdi Ermolo
Department of Neurosurgery, St. Peter's Specialized Hospital, Addis Ababa, Ethiopia
1 shared publication- Agnieszka Bronisz
Mossakowski Medical Research Institute, Polish Academy of Sciences, 02-106 Warsaw, Poland
1 shared publication
Latest Publications
- Open Access
- 20 July 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (3)
Sequential bilateral common carotid artery occlusion in protein C deficiency and patent foramen ovale: illustrative case
BACKGROUND: Common carotid artery occlusion (CCAO) is rare, with bilateral involvement being exceedingly uncommon. Its etiologies are heterogeneous, and sequential bilateral CCAO is exceptionally rare. Protein C deficiency is an inherited thrombophilia primarily associated with venous thromboembolism, while its role in arterial thrombosis remains unclear. In the presence of a patent foramen ovale (PFO), paradoxical embolism may contribute to arterial ischemic events. OBSERVATIONS: A 56-year-old man presented with sudden-onset motor aphasia and right hemiparesis. MR angiography demonstrated loss of flow in the left internal carotid and middle cerebral arteries. Digital subtraction angiography revealed a left CCAO proximal to the bifurcation. Emergency aspiration thrombectomy achieved recanalization, followed by carotid artery stenting for residual stenosis at the internal carotid artery origin. On postoperative day 7, he developed new neurological deficits; imaging showed occlusion of the brachiocephalic artery and right common carotid artery (CCA) with a new infarction in the right basal ganglia. Laboratory evaluation revealed protein C deficiency, and transesophageal echocardiography identified a PFO. LESSONS: Protein C deficiency in the presence of a PFO may predispose to recurrent paradoxical embolism, resulting in sequential bilateral CCAO. In cases of recurrent cryptogenic large-vessel occlusion with atypical vascular patterns, evaluation for thrombophilia and right-to-left shunt should be considered. https://thejns.org/doi/10.3171/CASE26378
- 20 July 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 12 (3)
Open AccessSequential bilateral common carotid artery occlusion in protein C deficiency and patent foramen ovale: illustrative case
BACKGROUND: Common carotid artery occlusion (CCAO) is rare, with bilateral involvement being exceedingly uncommon. Its etiologies are heterogeneous, and sequential bilateral CCAO is exceptionally rare. Protein C deficiency is an inherited thrombophilia primarily associated with venous thromboembolism, while its role in arterial thrombosis remains unclear. In the presence of a patent foramen ovale (PFO), paradoxical embolism may contribute to arterial ischemic events. OBSERVATIONS: A 56-year-old man presented with sudden-onset motor aphasia and right hemiparesis. MR angiography demonstrated loss of flow in the left internal carotid and middle cerebral arteries. Digital subtraction angiography revealed a left CCAO proximal to the bifurcation. Emergency aspiration thrombectomy achieved recanalization, followed by carotid artery stenting for residual stenosis at the internal carotid artery origin. On postoperative day 7, he developed new neurological deficits; imaging showed occlusion of the brachiocephalic artery and right common carotid artery (CCA) with a new infarction in the right basal ganglia. Laboratory evaluation revealed protein C deficiency, and transesophageal echocardiography identified a PFO. LESSONS: Protein C deficiency in the presence of a PFO may predispose to recurrent paradoxical embolism, resulting in sequential bilateral CCAO. In cases of recurrent cryptogenic large-vessel occlusion with atypical vascular patterns, evaluation for thrombophilia and right-to-left shunt should be considered. https://thejns.org/doi/10.3171/CASE26378
- Open Access
- 25 May 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (21)
Rapid development of a de novo vertebral artery dissecting aneurysm after contralateral vertebral artery occlusion: illustrative case
BACKGROUND: Developing a de novo vertebral artery (VA) dissecting aneurysm (VADA) after occlusion of the contralateral VA due to VADA is rare. The underlying mechanism and optimal treatment strategy remain unclear. OBSERVATIONS: A 52-year-old male presented with headache and was diagnosed with a right VADA that had progressed to complete arterial occlusion. Imaging at that time demonstrated no abnormality in the left VA. Six weeks later, the patient developed recurrent symptoms, and follow-up imaging revealed a newly formed left VADA. Because the posterior inferior cerebellar artery originated adjacent to the lesion and the contralateral VA was already occluded, stent-assisted coiling (SAC) was performed to preserve the parent artery. The patient was discharged without neurological deficit, and 1-year follow-up angiography demonstrated patency of the left VA and no recurrence. A review of the literature identified 10 previously reported cases; earlier cases were often managed conservatively and were associated with poor outcomes, whereas more recent cases treated with SAC demonstrated favorable outcomes. LESSONS: De novo VADA may develop rapidly after contralateral VA occlusion, likely due to altered hemodynamic stress. Thus, careful vascular surveillance is essential. When parent artery occlusion is not feasible, reconstructive endovascular strategies such as SAC may provide an effective flow-preserving treatment option. https://thejns.org/doi/10.3171/CASE26231
- 25 May 2026
- Published by Journal of Neurosurgery Publishing Group (JNSPG) in Journal of Neurosurgery: Case Lessons
- Vol. 11 (21)
Open AccessRapid development of a de novo vertebral artery dissecting aneurysm after contralateral vertebral artery occlusion: illustrative case
BACKGROUND: Developing a de novo vertebral artery (VA) dissecting aneurysm (VADA) after occlusion of the contralateral VA due to VADA is rare. The underlying mechanism and optimal treatment strategy remain unclear. OBSERVATIONS: A 52-year-old male presented with headache and was diagnosed with a right VADA that had progressed to complete arterial occlusion. Imaging at that time demonstrated no abnormality in the left VA. Six weeks later, the patient developed recurrent symptoms, and follow-up imaging revealed a newly formed left VADA. Because the posterior inferior cerebellar artery originated adjacent to the lesion and the contralateral VA was already occluded, stent-assisted coiling (SAC) was performed to preserve the parent artery. The patient was discharged without neurological deficit, and 1-year follow-up angiography demonstrated patency of the left VA and no recurrence. A review of the literature identified 10 previously reported cases; earlier cases were often managed conservatively and were associated with poor outcomes, whereas more recent cases treated with SAC demonstrated favorable outcomes. LESSONS: De novo VADA may develop rapidly after contralateral VA occlusion, likely due to altered hemodynamic stress. Thus, careful vascular surveillance is essential. When parent artery occlusion is not feasible, reconstructive endovascular strategies such as SAC may provide an effective flow-preserving treatment option. https://thejns.org/doi/10.3171/CASE26231
- Open Access
- 5 May 2026
- Published by Elsevier in World Neurosurgery
- Vol. 211, 125026
A Low-Cost Fresh Porcine Head Model for Introductory Anatomical Teaching of Selected Cranial Approaches
- 5 May 2026
- Published by Elsevier in World Neurosurgery
- Vol. 211, 125026
Open AccessA Low-Cost Fresh Porcine Head Model for Introductory Anatomical Teaching of Selected Cranial Approaches
- 31 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (698) , eade8732
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas
Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first established PTEN-deficient melanoma brain metastasis mouse models and characterized them to be more immunosuppressive compared with primary melanoma, mimicking the clinical settings. Next, we developed an allogeneic twin stem cell (TSC) system composed of two tumor-targeting stem cell (SC) populations. One SC was loaded with oncolytic herpes simplex virus (oHSV), and the other SC was CRISPR-Cas9 gene-edited to knock out nectin 1 (N1) receptor (N1 KO ) to acquire resistance to oHSV and release immunomodulators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF). Using mouse models of brain metastatic BRAF V600E /PTEN −/− and BRAF V600E/wt /PTEN −/− mutant melanomas, we show that locoregional delivery of TSCs releasing oHSV and GM-CSF (TSC-G) activated dendritic cell– and T cell–mediated immune responses. In addition, our strategy exhibited greater therapeutic efficacy when compared with the existing oncolytic viral therapeutic approaches. Moreover, the TSCs composed of SC-oHSV and SC N1KO –releasing GM-CSF and single-chain variable fragment anti–PD-1 (TSC-G/P) had therapeutic efficacy in both syngeneic and patient-derived humanized mouse models of leptomeningeal metastasis. Our findings provide a promising allogeneic SC-based immunotherapeutic strategy against melanomas in the CNS and a road map toward clinical translation.
- 31 May 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (698) , eade8732
Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas
Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first established PTEN-deficient melanoma brain metastasis mouse models and characterized them to be more immunosuppressive compared with primary melanoma, mimicking the clinical settings. Next, we developed an allogeneic twin stem cell (TSC) system composed of two tumor-targeting stem cell (SC) populations. One SC was loaded with oncolytic herpes simplex virus (oHSV), and the other SC was CRISPR-Cas9 gene-edited to knock out nectin 1 (N1) receptor (N1 KO ) to acquire resistance to oHSV and release immunomodulators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF). Using mouse models of brain metastatic BRAF V600E /PTEN −/− and BRAF V600E/wt /PTEN −/− mutant melanomas, we show that locoregional delivery of TSCs releasing oHSV and GM-CSF (TSC-G) activated dendritic cell– and T cell–mediated immune responses. In addition, our strategy exhibited greater therapeutic efficacy when compared with the existing oncolytic viral therapeutic approaches. Moreover, the TSCs composed of SC-oHSV and SC N1KO –releasing GM-CSF and single-chain variable fragment anti–PD-1 (TSC-G/P) had therapeutic efficacy in both syngeneic and patient-derived humanized mouse models of leptomeningeal metastasis. Our findings provide a promising allogeneic SC-based immunotherapeutic strategy against melanomas in the CNS and a road map toward clinical translation.
- Open Access
- 5 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (10) , eabe8671
Anti-EGFR VHH-armed death receptor ligand–engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers
Basal-like breast cancer (BLBC) shows brain metastatic (BM) capability and overexpresses EGFR and death-receptors 4/5 (DR4/5); however, the anatomical location of BM prohibits efficient drug-delivery to these targetable markers. In this study, we developed BLBC-BM mouse models featuring different patterns of BMs and explored the versatility of estem cell (SC)–mediated bi-functional EGFR and DR4/5-targeted treatment in these models. Most BLBC lines demonstrated a high sensitivity to EGFR and DR4/5 bi-targeting therapeutic protein, EVDRL [anti-EGFR VHH (EV) fused to DR ligand (DRL)]. Functional analyses using inhibitors and CRISPR-Cas9 knockouts revealed that the EV domain facilitated in augmenting DR4/5-DRL binding and enhancing DRL-induced apoptosis. EVDRL secreting stem cells alleviated tumor-burden and significantly increased survival in mouse models of residual-tumor after macrometastasis resection, perivascular niche micrometastasis, and leptomeningeal metastasis. This study reports mechanism based simultaneous targeting of EGFR and DR4/5 in BLBC and defines a new treatment paradigm for treatment of BM.
- 5 March 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (10) , eabe8671
Open AccessAnti-EGFR VHH-armed death receptor ligand–engineered allogeneic stem cells have therapeutic efficacy in diverse brain metastatic breast cancers
Basal-like breast cancer (BLBC) shows brain metastatic (BM) capability and overexpresses EGFR and death-receptors 4/5 (DR4/5); however, the anatomical location of BM prohibits efficient drug-delivery to these targetable markers. In this study, we developed BLBC-BM mouse models featuring different patterns of BMs and explored the versatility of estem cell (SC)–mediated bi-functional EGFR and DR4/5-targeted treatment in these models. Most BLBC lines demonstrated a high sensitivity to EGFR and DR4/5 bi-targeting therapeutic protein, EVDRL [anti-EGFR VHH (EV) fused to DR ligand (DRL)]. Functional analyses using inhibitors and CRISPR-Cas9 knockouts revealed that the EV domain facilitated in augmenting DR4/5-DRL binding and enhancing DRL-induced apoptosis. EVDRL secreting stem cells alleviated tumor-burden and significantly increased survival in mouse models of residual-tumor after macrometastasis resection, perivascular niche micrometastasis, and leptomeningeal metastasis. This study reports mechanism based simultaneous targeting of EGFR and DR4/5 in BLBC and defines a new treatment paradigm for treatment of BM.